Insider Transactions in Q1 2021 at Hca Healthcare, Inc. (HCA)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2021
|
Jon M Foster EVP and COO |
SELL
Open market or private sale
|
Direct |
5,432
-35.57%
|
$1,010,352
$186.18 P/Share
|
|
Mar 08
2021
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,568
-30.08%
|
$1,241,352
$189.21 P/Share
|
|
Mar 08
2021
|
Jon M Foster EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+35.46%
|
$564,000
$47.97 P/Share
|
|
Mar 08
2021
|
Wayne Joseph Riley Director |
SELL
Open market or private sale
|
Direct |
1,650
-13.23%
|
$313,500
$190.0 P/Share
|
|
Feb 24
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Bona fide gift
|
Direct |
433
-1.54%
|
-
|
|
Feb 24
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
73,853
-5.59%
|
$12,998,128
$176.72 P/Share
|
|
Feb 23
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
SELL
Open market or private sale
|
Direct |
5,751
-26.38%
|
$1,000,674
$174.95 P/Share
|
|
Feb 19
2021
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Open market or private sale
|
Direct |
6,692
-66.44%
|
$1,177,792
$176.05 P/Share
|
|
Feb 19
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Open market or private sale
|
Direct |
3,200
-10.2%
|
$566,400
$177.06 P/Share
|
|
Feb 18
2021
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-11.44%
|
$226,374
$174.61 P/Share
|
|
Feb 18
2021
|
Jennifer Berres SVP & Chief Human Res. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,306
+22.52%
|
-
|
|
Feb 18
2021
|
Phillip G Billington SVP-Internal Audit Services |
SELL
Payment of exercise price or tax liability
|
Direct |
3,164
-7.88%
|
$550,536
$174.61 P/Share
|
|
Feb 18
2021
|
Phillip G Billington SVP-Internal Audit Services |
BUY
Grant, award, or other acquisition
|
Direct |
10,146
+11.91%
|
-
|
|
Feb 18
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,583
-13.15%
|
$971,442
$174.61 P/Share
|
|
Feb 18
2021
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,186
+25.05%
|
-
|
|
Feb 18
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,360
-20.31%
|
$410,640
$174.61 P/Share
|
|
Feb 18
2021
|
Jane D. Englebright SVP and Chief Nursing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,111
+41.11%
|
-
|
|
Feb 18
2021
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,384
-39.35%
|
$1,110,816
$174.61 P/Share
|
|
Feb 18
2021
|
Jon M Foster EVP and COO |
BUY
Grant, award, or other acquisition
|
Direct |
16,222
+50.0%
|
-
|
|
Feb 18
2021
|
Charles J Hall Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,384
-2.87%
|
$1,110,816
$174.61 P/Share
|
|
Feb 18
2021
|
Charles J Hall Group President |
BUY
Grant, award, or other acquisition
|
Direct |
16,222
+6.8%
|
-
|
|
Feb 18
2021
|
Samuel N Hazen CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,282
-5.77%
|
$3,181,068
$174.61 P/Share
|
|
Feb 18
2021
|
Samuel N Hazen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,635
+13.3%
|
-
|
|
Feb 18
2021
|
A Bruce Moore Jr Group President - Service Line |
SELL
Payment of exercise price or tax liability
|
Direct |
5,583
-4.65%
|
$971,442
$174.61 P/Share
|
|
Feb 18
2021
|
A Bruce Moore Jr Group President - Service Line |
BUY
Grant, award, or other acquisition
|
Direct |
14,186
+10.57%
|
-
|
|
Feb 18
2021
|
Sandra L. Morgan SVP-Provider Relations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,567
-13.41%
|
$272,658
$174.61 P/Share
|
|
Feb 18
2021
|
Sandra L. Morgan SVP-Provider Relations |
BUY
Grant, award, or other acquisition
|
Direct |
6,091
+34.26%
|
-
|
|
Feb 18
2021
|
J William Morrow SVP - Finance and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,567
-21.93%
|
$272,658
$174.61 P/Share
|
|
Feb 18
2021
|
J William Morrow SVP - Finance and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
6,091
+46.02%
|
-
|
|
Feb 18
2021
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,788
-27.1%
|
$833,112
$174.61 P/Share
|
|
Feb 18
2021
|
P. Martin Paslick SVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
12,166
+40.78%
|
-
|
|
Feb 18
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,583
-8.18%
|
$971,442
$174.61 P/Share
|
|
Feb 18
2021
|
Jonathan B Perlin Pres-Clinical Operations & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
14,186
+17.21%
|
-
|
|
Feb 18
2021
|
Deborah M Reiner SVP - Mktg. & Communications |
SELL
Payment of exercise price or tax liability
|
Direct |
1,567
-13.54%
|
$272,658
$174.61 P/Share
|
|
Feb 18
2021
|
Deborah M Reiner SVP - Mktg. & Communications |
BUY
Grant, award, or other acquisition
|
Direct |
6,091
+34.48%
|
-
|
|
Feb 18
2021
|
Bill B Rutherford CFO and EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
11,522
-23.12%
|
$2,004,828
$174.61 P/Share
|
|
Feb 18
2021
|
Bill B Rutherford CFO and EVP |
BUY
Grant, award, or other acquisition
|
Direct |
31,419
+38.67%
|
-
|
|
Feb 18
2021
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,160
-20.36%
|
$549,840
$174.61 P/Share
|
|
Feb 18
2021
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,147
+39.54%
|
-
|
|
Feb 18
2021
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,192
-14.18%
|
$555,408
$174.61 P/Share
|
|
Feb 18
2021
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Grant, award, or other acquisition
|
Direct |
8,111
+26.49%
|
-
|
|
Feb 18
2021
|
Robert A Waterman SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,583
-1.56%
|
$971,442
$174.61 P/Share
|
|
Feb 18
2021
|
Robert A Waterman SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
14,186
+3.81%
|
-
|
|
Feb 18
2021
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,575
-20.87%
|
$448,050
$174.61 P/Share
|
|
Feb 18
2021
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,322
+29.68%
|
-
|
|
Feb 18
2021
|
Christopher F. Wyatt SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
2,360
-6.99%
|
$410,640
$174.61 P/Share
|
|
Feb 18
2021
|
Christopher F. Wyatt SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
8,111
+19.38%
|
-
|
|
Feb 16
2021
|
Jennifer Berres SVP & Chief Human Res. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,633
-48.62%
|
$1,328,142
$174.0 P/Share
|
|
Feb 16
2021
|
Jennifer Berres SVP & Chief Human Res. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,325
+36.92%
|
$830,850
$58.47 P/Share
|
|
Feb 12
2021
|
Charles J Hall Group President |
SELL
Bona fide gift
|
Direct |
5,736
-2.66%
|
-
|